Dapagliflozin Approved to Reduce Hospitalization in Diabetes Patients
October 22, 2019
Reduces risk for heart failure and cardiovascular disease hospitalizations.
SUBSCRIBE: Print / Digital / eNewsletter
Reduces risk for heart failure and cardiovascular disease hospitalizations.
Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.